fluoxetine has been researched along with Cognition Disorders in 46 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study compared nortriptyline and fluoxetine with placebo in the treatment of depression and in recovery from physical and cognitive impairments after stroke." | 9.09 | Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. ( Castillo, C; Curdue, K; Kopel, T; Kosier, JT; Newman, RM; Petracca, G; Robinson, RG; Schultz, SK; Starkstein, SE, 2000) |
| "Down syndrome is caused by triplication of chromosome 21 and is associated with neurocognitive phenotypes ranging from severe intellectual disability to various patterns of more selective neuropsychological deficits, including memory impairments." | 5.38 | Adult-onset fluoxetine treatment does not improve behavioral impairments and may have adverse effects on the Ts65Dn mouse model of Down syndrome. ( Ehninger, D; Heinen, M; Hettich, MM; Paesler, K; Ryan, DP; Schnell, S, 2012) |
| "This study compared nortriptyline and fluoxetine with placebo in the treatment of depression and in recovery from physical and cognitive impairments after stroke." | 5.09 | Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. ( Castillo, C; Curdue, K; Kopel, T; Kosier, JT; Newman, RM; Petracca, G; Robinson, RG; Schultz, SK; Starkstein, SE, 2000) |
| " During adulthood, SFR and IMS mice received chronic treatment (∼3 weeks) with the selective serotonin reuptake inhibitor (SSRI) fluoxetine (18 mg/kg/day), and were assessed for anxiety- and depression-related behavior in the light/dark test and forced swim tests (FST), respectively." | 3.77 | Infant maternal separation impairs adult cognitive performance in BALB/cJ mice. ( Dulawa, SC; Jiao, J; Wang, L, 2011) |
| "Two individuals from a large HD pedigree with a very high prevalence of obsessive-compulsive disorder (OCD) have been treated with fluoxetine, an SSRI." | 3.71 | Fluoxetine in the treatment of Huntington's disease. ( Daniele, F; De Marchi, N; Ragone, MA, 2001) |
| "Depression is a highly prevalent concomitant of dementia." | 2.40 | Depression and dementia: comorbidities, identification, and treatment. ( Meyers, BS, 1998) |
| " The aim of the study was to establish whether combined single and chronic administration of aripiprazole (ARI) and fluoxetine (FLU) affects animal locomotor activity or modifies spatial memory functions in female rats exposed to ethyl alcohol." | 1.46 | Effect of combined administration of aripiprazole and fluoxetine on cognitive functions in female rats exposed to ethyl alcohol. ( Czaja, N; Kus, K; Nowakowska, E; Ratajczak, P; Zaprutko, T, 2017) |
| "Post-traumatic stress disorder (PTSD) is a condition that develops after an individual has experienced a major trauma." | 1.46 | Effects of moderate treadmill exercise and fluoxetine on behavioural and cognitive deficits, hypothalamic-pituitary-adrenal axis dysfunction and alternations in hippocampal BDNF and mRNA expression of apoptosis - related proteins in a rat model of post-tr ( Bandegi, AR; Hosseini-Khah, Z; Mohammadkhani, R; Rafiei, A; Rashidy-Pour, A; Samaei, SA; Shafia, S; Vafaei, AA; Valadan, R, 2017) |
| "5-Fluorouracil (5-FU) is a cytostatic drug associated with chemotherapy-induced cognitive impairments that many cancer patients experience after treatment." | 1.38 | Fluoxetine counteracts the cognitive and cellular effects of 5-fluorouracil in the rat hippocampus by a mechanism of prevention rather than recovery. ( Bennett, G; ElBeltagy, M; Lyons, L; Wigmore, P, 2012) |
| "Down syndrome is caused by triplication of chromosome 21 and is associated with neurocognitive phenotypes ranging from severe intellectual disability to various patterns of more selective neuropsychological deficits, including memory impairments." | 1.38 | Adult-onset fluoxetine treatment does not improve behavioral impairments and may have adverse effects on the Ts65Dn mouse model of Down syndrome. ( Ehninger, D; Heinen, M; Hettich, MM; Paesler, K; Ryan, DP; Schnell, S, 2012) |
| "The fluoxetine-treated brain was found to show marked repressions of microglia activation, neutrophil infiltration, and proinflammatory marker expressions." | 1.35 | Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. ( Kim, C; Kim, SW; Lee, JK; Lim, CM; Park, JY; Yoon, SH, 2009) |
| "Depression was induced by two models, (i) 60 days social isolation of litter; and ii) by applying chronic unpredictable mild stress for 21 days." | 1.32 | Evaluation of cognitive function of fluoxetine, sertraline and tianeptine in isolation and chronic unpredictable mild stress-induced depressive Wistar rats. ( Kumar, SN; Ramanathan, M; Suresh, B, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (17.39) | 18.2507 |
| 2000's | 18 (39.13) | 29.6817 |
| 2010's | 20 (43.48) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kus, K | 1 |
| Ratajczak, P | 1 |
| Czaja, N | 1 |
| Zaprutko, T | 1 |
| Nowakowska, E | 1 |
| Mao, M | 1 |
| Li, S | 1 |
| Zong, M | 1 |
| Qiu, L | 1 |
| Yang, J | 2 |
| Xia, J | 1 |
| Ji, M | 1 |
| Malik, O | 1 |
| Westphal, B | 1 |
| Trofimiuk, E | 1 |
| Braszko, JJ | 1 |
| Epelbaum, S | 1 |
| Dubois, B | 1 |
| Wagner, GJ | 1 |
| Ngo, VK | 1 |
| Nakasujja, N | 1 |
| Akena, D | 1 |
| Aunon, F | 1 |
| Musisi, S | 1 |
| Li, Y | 2 |
| Abdourahman, A | 1 |
| Tamm, JA | 1 |
| Pehrson, AL | 1 |
| Sánchez, C | 1 |
| Gulinello, M | 1 |
| Yu, L | 1 |
| An, C | 1 |
| Jia, L | 1 |
| Chen, Q | 1 |
| Zhen, F | 1 |
| Wang, S | 1 |
| Wang, M | 1 |
| Yun, HM | 1 |
| Park, KR | 1 |
| Kim, EC | 1 |
| Kim, S | 1 |
| Hong, JT | 1 |
| Luo, P | 1 |
| Zhang, X | 1 |
| Lu, Y | 1 |
| Chen, C | 1 |
| Li, C | 1 |
| Zhou, M | 1 |
| Lu, Q | 1 |
| Xu, X | 1 |
| Shen, G | 1 |
| Guo, L | 1 |
| Xu, C | 1 |
| Liu, X | 1 |
| Song, X | 1 |
| Gao, Q | 1 |
| Cheng, L | 1 |
| Wang, L | 2 |
| Zhang, K | 1 |
| Xu, Y | 1 |
| Jin, L | 1 |
| Gao, LF | 1 |
| Sun, DS | 1 |
| Wu, H | 1 |
| Wang, Q | 1 |
| Ke, D | 1 |
| Lei, H | 1 |
| Wang, JZ | 1 |
| Liu, GP | 1 |
| Shafia, S | 1 |
| Vafaei, AA | 1 |
| Samaei, SA | 1 |
| Bandegi, AR | 1 |
| Rafiei, A | 1 |
| Valadan, R | 1 |
| Hosseini-Khah, Z | 1 |
| Mohammadkhani, R | 1 |
| Rashidy-Pour, A | 1 |
| Li, WL | 1 |
| Cai, HH | 1 |
| Wang, B | 1 |
| Chen, L | 1 |
| Zhou, QG | 1 |
| Luo, CX | 1 |
| Liu, N | 1 |
| Ding, XS | 1 |
| Zhu, DY | 1 |
| Lim, CM | 1 |
| Kim, SW | 1 |
| Park, JY | 1 |
| Kim, C | 1 |
| Yoon, SH | 1 |
| Lee, JK | 1 |
| Rozzini, L | 1 |
| Chilovi, BV | 1 |
| Conti, M | 1 |
| Bertoletti, E | 1 |
| Zanetti, M | 1 |
| Trabucchi, M | 1 |
| Padovani, A | 1 |
| Ayala, ME | 1 |
| Ginsburg, GS | 1 |
| Silva, SG | 1 |
| Jacobs, RH | 1 |
| Tonev, S | 1 |
| Hoyle, RH | 1 |
| Kingery, JN | 1 |
| Reinecke, MA | 1 |
| Curry, JF | 1 |
| March, JS | 1 |
| Nikiforuk, A | 1 |
| Popik, P | 1 |
| Patti, F | 1 |
| Leone, C | 1 |
| D'Amico, E | 1 |
| Jiao, J | 1 |
| Dulawa, SC | 1 |
| Lyons, L | 1 |
| ElBeltagy, M | 1 |
| Bennett, G | 1 |
| Wigmore, P | 1 |
| Heinen, M | 1 |
| Hettich, MM | 1 |
| Ryan, DP | 1 |
| Schnell, S | 1 |
| Paesler, K | 1 |
| Ehninger, D | 1 |
| Ledo, JH | 1 |
| Azevedo, EP | 1 |
| Clarke, JR | 1 |
| Ribeiro, FC | 1 |
| Figueiredo, CP | 1 |
| Foguel, D | 1 |
| De Felice, FG | 1 |
| Ferreira, ST | 1 |
| Horsfield, SA | 1 |
| Rosse, RB | 1 |
| Tomasino, V | 1 |
| Schwartz, BL | 1 |
| Mastropaolo, J | 1 |
| Deutsch, SI | 1 |
| Doraiswamy, PM | 1 |
| Krishnan, KR | 1 |
| Oxman, T | 1 |
| Jenkyn, LR | 1 |
| Coffey, DJ | 1 |
| Burt, T | 1 |
| Clary, CM | 1 |
| Ramanathan, M | 1 |
| Kumar, SN | 1 |
| Suresh, B | 1 |
| Fontenelle, LF | 1 |
| Mendlowicz, MV | 1 |
| Versiani, M | 1 |
| Moore, TL | 1 |
| Schettler, SP | 1 |
| Killiany, RJ | 1 |
| Herndon, JG | 1 |
| Luebke, JI | 1 |
| Moss, MB | 1 |
| Rosene, DL | 1 |
| Boggio, PS | 1 |
| Fregni, F | 1 |
| Bermpohl, F | 1 |
| Mansur, CG | 1 |
| Rosa, M | 1 |
| Rumi, DO | 1 |
| Barbosa, ER | 1 |
| Odebrecht Rosa, M | 1 |
| Pascual-Leone, A | 1 |
| Rigonatti, SP | 1 |
| Marcolin, MA | 1 |
| Araujo Silva, MT | 1 |
| Grote, HE | 1 |
| Bull, ND | 1 |
| Howard, ML | 1 |
| van Dellen, A | 1 |
| Blakemore, C | 1 |
| Bartlett, PF | 1 |
| Hannan, AJ | 1 |
| Cavedini, P | 1 |
| Zorzi, C | 1 |
| Bassi, T | 1 |
| Gorini, A | 1 |
| Baraldi, C | 1 |
| Ubbiali, A | 1 |
| Bellodi, L | 1 |
| Farabaugh, A | 2 |
| Mischoulon, D | 1 |
| Schwartz, F | 1 |
| Pender, M | 1 |
| Fava, M | 2 |
| Alpert, J | 1 |
| Narushima, K | 1 |
| Paradiso, S | 1 |
| Moser, DJ | 1 |
| Jorge, R | 1 |
| Robinson, RG | 3 |
| Candrian, M | 1 |
| Pizzagalli, DA | 1 |
| Baer, L | 1 |
| Geldmacher, DS | 1 |
| Waldman, AJ | 1 |
| Doty, L | 1 |
| Heilman, KM | 1 |
| Geretsegger, C | 1 |
| Böhmer, F | 1 |
| Ludwig, M | 1 |
| Yoshida, K | 1 |
| Smith, B | 1 |
| Craggs, M | 1 |
| Kumar, RC | 1 |
| Meyers, BS | 1 |
| Schultz, SK | 1 |
| Castillo, C | 1 |
| Kopel, T | 1 |
| Kosier, JT | 1 |
| Newman, RM | 1 |
| Curdue, K | 1 |
| Petracca, G | 1 |
| Starkstein, SE | 1 |
| Dunkin, JJ | 1 |
| Leuchter, AF | 1 |
| Cook, IA | 1 |
| Kasl-Godley, JE | 1 |
| Abrams, M | 1 |
| Rosenberg-Thompson, S | 1 |
| De Marchi, N | 1 |
| Daniele, F | 1 |
| Ragone, MA | 1 |
| Shafey, H | 1 |
| Mirow, S | 1 |
| Austin, LS | 1 |
| Arana, GW | 1 |
| Melvin, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT03007303] | 30 participants (Anticipated) | Observational [Patient Registry] | 2016-06-30 | Recruiting | |||
| Effect of Serotonin and Levodopa Functional Recovery in Patients With Cerebral Infarction[NCT02386475] | Phase 4 | 39 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Double-Blind, Placebo-Controlled, Randomized Trial of Adjunctive Lisdexamfetamine Dimesylate in Residual Symptoms of Major Depressive Disorder Partially Responsive to Selective Serotonin or Norepinephrine Reuptake Inhibitor Monotherapy[NCT01148979] | Phase 4 | 35 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Investigating the Efficacy of a Top-Down Approach to Cognitive Remediation in Individuals With Affective Disorders[NCT02502604] | 58 participants (Actual) | Interventional | 2015-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Montgomery-Asberg Depression Rating Scale Dysphoric Apathy Retardation subfactor (MDAR) is a 5-item subscale of the clinician-administered 10-item Montgomery-Asberg Depression Rating Scale (MADRS). MDAR score can range from 0-30 with a higher score representing a greater severity of depressive symptoms. (NCT01148979)
Timeframe: Baseline to 4 weeks of treatment
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Baseline Mean MDAR score | Week 4 Mean MDAR score | Change from BL in mean MDAR score | |
| Lisdexamfetamine Dimesylate (Vyvanse) | 13.46 | 6.36 | -7.08 |
| Placebo Adjunct | 12.57 | 9.08 | -3.49 |
4 reviews available for fluoxetine and Cognition Disorders
| Article | Year |
|---|---|
[Subjective cognitive complaint. From anxiety to prodromal Alzheimer's disease?].
Topics: Aged; Alzheimer Disease; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cognition Diso | 2013 |
Treatment options of cognitive impairment in multiple sclerosis.
Topics: Cholinesterase Inhibitors; Cognition Disorders; Fluoxetine; Humans; Interferon-beta; Memantine; Mult | 2010 |
Treatment issues in poststroke depression.
Topics: Activities of Daily Living; Antidepressive Agents; Cerebrovascular Disorders; Cognition Disorders; D | 1998 |
Depression and dementia: comorbidities, identification, and treatment.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Benzamides; Citalopram; Clomipramine; Cog | 1998 |
9 trials available for fluoxetine and Cognition Disorders
| Article | Year |
|---|---|
Cognitive measures of adolescent depression: unique or unitary constructs?
Topics: Adolescent; Child; Cognition Disorders; Cognitive Behavioral Therapy; Culture; Depressive Disorder, | 2009 |
Does antidepressant therapy improve cognition in elderly depressed patients?
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Cognition; Cognition Disorders; Confidence Intervals | 2003 |
Effect of repetitive TMS and fluoxetine on cognitive function in patients with Parkinson's disease and concurrent depression.
Topics: Aged; Antiparkinson Agents; Cognition Disorders; Depressive Disorder, Major; Double-Blind Method; Fe | 2005 |
Dysfunctional attitudes and personality disorder comorbidity during long-term treatment of MDD.
Topics: Adult; Antidepressive Agents, Second-Generation; Attitude; Cognition Disorders; Cognitive Behavioral | 2007 |
Effect of antidepressant therapy on executive function after stroke.
Topics: Aged; Antidepressive Agents; Cognition Disorders; Double-Blind Method; Female; Fluoxetine; Humans; M | 2007 |
Perceived stress and cognitive vulnerability mediate the effects of personality disorder comorbidity on treatment outcome in major depressive disorder: a path analysis study.
Topics: Acute Disease; Adolescent; Adult; Ambulatory Care; Cognition Disorders; Comorbidity; Depressive Diso | 2007 |
Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects.
Topics: Aged; Aged, 80 and over; Cognition Disorders; Depressive Disorder; Double-Blind Method; Female; Fluo | 1994 |
Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study.
Topics: Activities of Daily Living; Antidepressive Agents, Tricyclic; Cognition Disorders; Depressive Disord | 2000 |
Executive dysfunction predicts nonresponse to fluoxetine in major depression.
Topics: Adult; Cognition Disorders; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Hum | 2000 |
Executive dysfunction predicts nonresponse to fluoxetine in major depression.
Topics: Adult; Cognition Disorders; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Hum | 2000 |
Executive dysfunction predicts nonresponse to fluoxetine in major depression.
Topics: Adult; Cognition Disorders; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Hum | 2000 |
Executive dysfunction predicts nonresponse to fluoxetine in major depression.
Topics: Adult; Cognition Disorders; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Hum | 2000 |
33 other studies available for fluoxetine and Cognition Disorders
| Article | Year |
|---|---|
Effect of combined administration of aripiprazole and fluoxetine on cognitive functions in female rats exposed to ethyl alcohol.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Avoidance Learning; Central Nervous System Depressants; | 2017 |
Two-hit model of postintensive care syndrome induced by lipopolysaccharide challenge and subsequent chronic unpredictable stress in mice.
Topics: Animals; Anxiety; Chronic Disease; Cognition Disorders; Corticosterone; Critical Care; Critical Illn | 2019 |
A role for selective serotonin reuptake inhibitors in the management of residual cognitive dysfunction in pediatric Cushing's disease.
Topics: Adolescent; Cognition Disorders; Female; Fluoxetine; Humans; Pituitary ACTH Hypersecretion; Selectiv | 2013 |
Concomitant docosahexaenoic acid administration ameliorates stress-induced cognitive impairment in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Cognition Disorders; Docosahexaenoic Aci | 2013 |
Impact of antidepressant therapy on cognitive aspects of work, condom use, and psychosocial well-being among HIV clients in Uganda.
Topics: Adult; Antidepressive Agents; Cognition Disorders; Condoms; Depressive Disorder, Major; Developing C | 2014 |
Reversal of age-associated cognitive deficits is accompanied by increased plasticity-related gene expression after chronic antidepressant administration in middle-aged mice.
Topics: Aging; Animals; Antidepressive Agents; Cell Proliferation; Cognition Disorders; Female; Fluoxetine; | 2015 |
Combination Therapy of Salvianolic Acid and Fluoxetine Improves the Cognitive Function of Rats with Chronic Stress-induced Depression.
Topics: Alkenes; Animals; Antidepressive Agents, Second-Generation; Chronic Disease; Cognition Disorders; De | 2016 |
Serotonin 6 receptor controls Alzheimer's disease and depression.
Topics: Adaptor Proteins, Signal Transducing; Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Amyloid Pre | 2015 |
Fluoxetine ameliorates cognitive impairments induced by chronic cerebral hypoperfusion via down-regulation of HCN2 surface expression in the hippocampal CA1 area in rats.
Topics: Animals; CA1 Region, Hippocampal; Carotid Stenosis; Cerebrovascular Circulation; Cerebrovascular Dis | 2016 |
Aberrant resting state in microRNA-30e rat model of cognitive impairment.
Topics: Animals; Cognition Disorders; Disease Models, Animal; Exploratory Behavior; Fluoxetine; Hippocampus; | 2016 |
Long-term Ameliorative Effects of the Antidepressant Fluoxetine Exposure on Cognitive Deficits in 3 × TgAD Mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antidepressive Agents; Brain-Derived Neurotrophic | 2017 |
Effects of moderate treadmill exercise and fluoxetine on behavioural and cognitive deficits, hypothalamic-pituitary-adrenal axis dysfunction and alternations in hippocampal BDNF and mRNA expression of apoptosis - related proteins in a rat model of post-tr
Topics: Animals; Apoptosis; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cognition; Cognition Disord | 2017 |
Chronic fluoxetine treatment improves ischemia-induced spatial cognitive deficits through increasing hippocampal neurogenesis after stroke.
Topics: Analysis of Variance; Animals; Antimetabolites; Bromodeoxyuridine; Cell Count; Cognition Disorders; | 2009 |
Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Cells, Cultured; Cognition Disorders; | 2009 |
Efficacy of SSRIs on cognition of Alzheimer's disease patients treated with cholinesterase inhibitors.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Citalopram; Cognition; Cognition Disorders; Depr | 2010 |
Brain serotonin, psychoactive drugs, and effects on reproduction.
Topics: Affect; Amphetamine-Related Disorders; Animals; Biological Clocks; Brain; Cognition Disorders; Depre | 2009 |
Long-lasting cognitive deficit induced by stress is alleviated by acute administration of antidepressants.
Topics: Animals; Antidepressive Agents; Attention; Behavior, Animal; Citalopram; Cognition Disorders; Desipr | 2011 |
Infant maternal separation impairs adult cognitive performance in BALB/cJ mice.
Topics: Age Factors; Animals; Animals, Newborn; Anxiety; Behavior, Animal; Cognition Disorders; Depression; | 2011 |
Fluoxetine counteracts the cognitive and cellular effects of 5-fluorouracil in the rat hippocampus by a mechanism of prevention rather than recovery.
Topics: Animals; Antidepressive Agents, Second-Generation; Antimetabolites, Antineoplastic; Body Weight; Bro | 2012 |
Adult-onset fluoxetine treatment does not improve behavioral impairments and may have adverse effects on the Ts65Dn mouse model of Down syndrome.
Topics: Animals; Behavior, Animal; Body Weight; Cell Count; Cognition Disorders; Down Syndrome; Female; Fluo | 2012 |
Amyloid-β oligomers link depressive-like behavior and cognitive deficits in mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anhedonia; Animals; Brain Chemistry; Cognition Disorders; | 2013 |
Fluoxetine's effects on cognitive performance in patients with traumatic brain injury.
Topics: Aged; Brain Injuries; Cognition Disorders; Fluoxetine; Humans; Male; Middle Aged; Pilot Projects; Se | 2002 |
Evaluation of cognitive function of fluoxetine, sertraline and tianeptine in isolation and chronic unpredictable mild stress-induced depressive Wistar rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Cognition Disorders; Depression; Female; Fluoxetin | 2003 |
Patients with obsessive-compulsive disorder (OCD) displayed cognitive deficits consistent with a dysfunction of the dorsolateral-striatal circuit.
Topics: Cognition Disorders; Corpus Striatum; Fluoxetine; Fluvoxamine; Frontal Lobe; Humans; Nerve Net; Neur | 2004 |
Cognitive impairment in aged rhesus monkeys associated with monoamine receptors in the prefrontal cortex.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Age Factors; Aging; Analysis of Variance; A | 2005 |
Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine.
Topics: Age Factors; Animals; Behavior, Animal; Cell Proliferation; Cells, Cultured; Cognition Disorders; De | 2005 |
Decision-making functioning as a predictor of treatment outcome in anorexia nervosa.
Topics: Adult; Anorexia Nervosa; Body Mass Index; Cognition Disorders; Cognitive Behavioral Therapy; Combine | 2006 |
Fluoxetine in dementia of the Alzheimer's type: prominent adverse effects and failure to improve cognition.
Topics: Aged; Alzheimer Disease; Cognition Disorders; Female; Fluoxetine; Humans; Male; Psychiatric Status R | 1994 |
Fluoxetine in breast-milk and developmental outcome of breast-fed infants.
Topics: Breast Feeding; Cognition Disorders; Developmental Disabilities; Female; Fluoxetine; Humans; Infant; | 1998 |
Fluoxetine in the treatment of Huntington's disease.
Topics: Affect; Aggression; Antidepressive Agents, Second-Generation; Cognition Disorders; Disease Progressi | 2001 |
The effect of fluoxetine in depression associated with multiple sclerosis.
Topics: Adult; Cognition Disorders; Depressive Disorder; Doxepin; Female; Fluoxetine; Humans; Multiple Scler | 1992 |
Cognitive dysfunction associated with fluoxetine.
Topics: Cognition Disorders; Depressive Disorder; Female; Fluoxetine; Humans; Learning; Memory, Short-Term; | 1991 |
Toxicity resulting from lithium augmentation of antidepressant treatment in elderly patients.
Topics: Aged; Antidepressive Agents; Cognition Disorders; Depressive Disorder; Drug Interactions; Drug Thera | 1990 |